Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe - What is Really Happening?

European Urology, Supplements

Volumn 6, Issue 6, 2007, Pages 446-453

  Djavan, Bob ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

blocker; 5 reductase inhibitor; Benign prostatic hyperplasia; Dihydrotestosterone; Disease progression; Guidelines; Lower urinary tract symptoms; Watchful waiting

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; TAMSULOSIN; TESTOSTERONE;

CLINICAL PRACTICE; CLINICAL STUDY; COST BENEFIT ANALYSIS; DISEASE COURSE; EARLY DIAGNOSIS; EUROPE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; PATIENT ASSESSMENT; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK REDUCTION; SYMPTOMATOLOGY; URINE RETENTION; UROLOGY;

EID: 33846809213     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.01.014     Document Type: Review

References (32)

1. Sarma A.V., Jacobson D.J., McGree M.E., et al. A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. J Urol 173 (2005) 2048-2053
2. Wei J.T., Calhoun E., and Jacobsen S.J. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 173 (2005) 1256-1261
3. Black L., Naslund M.J., Gilbert Jr. T.D., Davis E.A., and Ollendorf D.A. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 12 (2006) S99-S110
4. Chapple C.R. Lower urinary tract symptoms suggestive of benign prostatic obstruction-TRIUMPH: design and implementation. Eur Urol 39 Suppl 3 (2001) 31-36
5. van Exel N.J., Koopmanschap M.A., McDonnell J., et al. Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol 49 (2006) 92-102
6. Hutchison A., Farmer R., Chapple C., et al. Characteristics of patients presenting with LUTS/BPH in six European countries. Eur Urol 50 (2006) 555-561 discussion 62
7. Debruyne F.M.J. Medical management of BPH: the debate continues. Eur Urol 50 (2006) 416-417
8. de la Rosette JJ, Alivizatos G, Madersbacher S, et al. European Association of Urology: guidelines on benign prostatic hyperplasia. Update March 2004. Available at www.uroweb.nl. Accessed 22 January 2007.
9. Hutchison A., Farmer R., Verhamme K., Berges R., and Navarrete R.V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 51 (2007) 207-216
10. Montorsi F., and Moncada I. Safety and tolerability of treatment for BPH. Eur Urol Suppl 5 (2006) 1004-1012
11. Emberton M., Andriole G.L., de la Rosette J., et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 61 (2003) 267-273
12. Rhodes T., Girman C.J., Jacobsen S.J., et al. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 161 (1999) 1174-1179
13. Jacobsen S.J., Girman C.J., Guess H.A., et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 155 (1996) 595-600
14. Roberts R.O., Jacobsen S.J., Jacobson D.J., et al. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 163 (2000) 107-113
15. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
16. Crawford E.D., Wilson S.S., McConnell J.D., et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175 (2006) 1422-1426 discussion 6-7
17. Roehrborn C.G. Definition of at-risk patients: baseline variables. BJU Int 97 Suppl 2 (2006) 7-11 discussion 21-2
18. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170 (2003) 530-547
19. Flanigan R.C., Reda D.J., Wasson J.H., et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 160 (1998) 12-16 discussion 6-7
20. Djavan B., Fong Y.K., Harik M., et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 64 (2004) 1144-1148
21. Djavan B., Fong Y.K., Chaudry A., et al. Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting. World J Urol 23 (2005) 253-256
22. Slawin K.M., and Kattan M.W. The use of nomograms for selecting BPH candidates for dutasteride therapy. Rev Urol 6 Suppl 9 (2004) S40-S45
23. Roehrborn C.G., Boyle P., Gould A.L., and Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53 (1999) 581-589
24. Roehrborn C.G., McConnell J., Bonilla J., et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 163 (2000) 13-20
25. Fong Y.K., Milani S., and Djavan B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol 15 (2005) 35-38
26. Imperato-McGinley J., and Zhu Y.S. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 198 (2002) 51-59
27. Iehle C., Radvanyi F., Gil Diez de Medina S., et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol 68 (1999) 189-195
28. Frye S.V. Discovery and clinical development of dutasteride, a potent dual 5alpha-reductase inhibitor. Curr Top Med Chem 6 (2006) 405-421
29. McConnell J.D., Bruskewitz R., Walsh P., et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557-563
30. Roehrborn C.G., Boyle P., Nickel J.C., Hoefner K., and Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
31. Roehrborn C.G., and Lotan Y. The motion: prevention of prostate cancer with a 5α-reductase inhibitor is feasible. Eur Urol 49 (2006) 396-400
32. Novara G., Galfano A., Gardi M., et al. Critical review of guidelines for BPH diagnosis and treatment strategy. Eur Urol Suppl 5 (2006) 418-429